XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorXilio Development, Inc.
About this trial
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors.
Eligibility criteria
Qualifiers
Measurable disease at baseline per RECIST v1.1
ECOG performance status of 0 or 1
Adequate organ function
Must have histologically confirmed metastatic NSCLC.
Disqualifiers
Prior treatment with IL-2
History of significant pulmonary disease
History of clinically significant cardiovascular disease
Active CNS metastases
Trial design
Treatments tested in this trial
- XTX501
Treatment groups
140 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov